Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.
Several classes of drugs that modify serotonin (5-HT) neurotransmission are either currently used, or are being evaluated for their potential use in the treatment of anxiety, schizophrenia, and depression. 5-HT1A agonists are considered potential anxiolytics, while some atypical antipsychotics are potent 5-HT2 antagonists (and also have modest dopamine D2 affinity). Furthermore, there is a diverse group of serotonergic drugs that may be effective antidepressants. Secretion of ACTH, corticosterone/cortisol, prolactin, renin, oxytocin and vasopressin are stimulated by activation of different 5-HT receptor subtypes, while other neurotransmitter receptors also influence the secretion of these hormones. We compared the receptor binding profiles of 5-HT anxiolytics, antipsychotics and antidepressants with their endocrine effects. These comparisons could aid in understanding both the therapeutic and side effects of these drugs.
Department of Pharmacology, Loyola University of Chicago, Stritch School of Medicine, Maywood, IL 60153.
A D
AD
Levy
L D
LD
Van de Kar
D014151:Anti-Anxiety Agents / Q000378:metabolism / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000378:metabolism / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000378:metabolism / Q000494:pharmacology*; D004702:Endocrine Glands / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000378:metabolism / Q000494:pharmacology
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin